NCT02549677View on ClinicalTrials.gov

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

PHASE4CompletedINTERVENTIONAL

Enrollment

294

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions

Breast Neoplasms

Interventions

DRUG

Epirubicin

epirubicin, 90mg per square meter, every 3 weeks, day 1

DRUG

Docetaxel

docetaxel, 75mg per square meter, every 3 weeks, day 1

DRUG

cyclophosphamide

cyclophosphamide, 600mg per square meter, every 3 weeks, day 1

Trial Locations (1)

200025

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT02549677 - Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer | Biotech Hunter | Biotech Hunter